Alexis K. de Haven Brandon

CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Mike I. Walton, Paul D. Eve, Angela Hayes et al. · Clinical Cancer Research · 2012 · 93 citations · Full text

Medicine, Oncology, Pharmacology +15

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Timothy A. Yap, Mike I. Walton, Kyla M. Grimshaw et al. · Clinical Cancer Research · 2012 · 91 citations · Full text

Medicine, Oncology, Pharmacology +17

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

Mike I. Walton, Paul D. Eve, Angela Hayes et al. · Oncotarget · 2015 · 69 citations · Full text

Medicine, Oncology, Pharmacology +14

Application of Meso Scale Technology for the Measurement of Phosphoproteins in Human Tumor Xenografts

Sharon Gowan, Anthea Hardcastle, Albert Hallsworth et al. · Assay and Drug Development Technologies · 2007 · 58 citations

Medicine, Oncology, Pharmacology +17

Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (<i>R</i>)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)

James Osborne, Thomas P. Matthews, Tatiana McHardy et al. · Journal of Medicinal Chemistry · 2016 · 38 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14